{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30.8"},{"groupId":"OG001","value":"19.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"747"},{"groupId":"OG001","value":"735"}],"units":"Participants"}],"title":"Acute RT and Hormone Toxicity: Grade 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"41.6"},{"groupId":"OG001","value":"49.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"747"},{"groupId":"OG001","value":"735"}],"units":"Participants"}],"title":"Acute RT and Hormone Toxicity: Grade 2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.1"},{"groupId":"OG001","value":"25.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"747"},{"groupId":"OG001","value":"735"}],"units":"Participants"}],"title":"Acute RT and Hormone Toxicity: Grade 3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"747"},{"groupId":"OG001","value":"735"}],"units":"Participants"}],"title":"Acute RT and Hormone Toxicity: Grade 4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"747"},{"groupId":"OG001","value":"735"}],"units":"Participants"}],"title":"Acute RT and Hormone Toxicity: Grade 5"},{"categories":[{"measurements":[{"groupId":"OG000","value":"34.0"},{"groupId":"OG001","value":"32.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"742"},{"groupId":"OG001","value":"724"}],"units":"Participants"}],"title":"Late RT Toxicity: Grade 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.5"},{"groupId":"OG001","value":"22.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"742"},{"groupId":"OG001","value":"724"}],"units":"Participants"}],"title":"Late RT Toxicity: Grade 2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.7"},{"groupId":"OG001","value":"8.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"742"},{"groupId":"OG001","value":"724"}],"units":"Participants"}],"title":"Late RT Toxicity: Grade 3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1"},{"groupId":"OG001","value":"0.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"742"},{"groupId":"OG001","value":"724"}],"units":"Participants"}],"title":"Late RT Toxicity: Grade 4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"742"},{"groupId":"OG001","value":"724"}],"units":"Participants"}],"title":"Late RT Toxicity: Grade 5"}],"denoms":[{"counts":[{"groupId":"OG000","value":"747"},{"groupId":"OG001","value":"735"}],"units":"Participants"}],"description":"Acute drug therapy and radiation (\\<= 90 days from start of RT) toxicity was graded using the Common Toxicity Criteria (CTC) v.2.0 criteria; late toxicity was graded using the Radiation Therapy Oncology Group (RTOG)/European Organisation for Research and Treatment of Cancer (EORTC) Late Radiation Morbidity Scoring schema. Grade refers to the severity of the toxicity. The CTC v2.0 assigns Grades 1 through 5 with unique clinical descriptions of severity for each toxicity based on this general guideline: Grade 1 Mild toxicity, Grade 2 Moderate toxicity, Grade 3 Severe toxicity, Grade 4 Life-threatening or disabling toxicity, Grade 5 Death related to toxicity. The highest grade acute and late toxicity was determined for each patient.","groups":[{"description":"Total Androgen Suppression (TAS) (LHRH agonist and Casodex or Eulexin) x 8 weeks followed by radiation therapy (RT) with concurrent TAS (LHRH agonist and Casodex or Eulexin).","id":"OG000","title":"TAS x 8 Weeks"},{"description":"TAS (LHRH agonist and Casodex or Eulexin) x 28 weeks followed by RT with concurrent TAS (LHRH agonist and Casodex or Eulexin).","id":"OG001","title":"TAS x 28 Weeks"}],"paramType":"NUMBER","populationDescription":"Eligible patients with adverse event data in corresponding time frame (during hormone therapy and \\<=90 days from RT start; \\> 90 days from RT start)","reportingStatus":"POSTED","timeFrame":"From randomization to 10 years. (Patients are followed until death or study termination, whichever occurs first.)","title":"Treatment-induced Morbidity (Highest Grade Toxicity Reported Per Patient)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}